Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (Symbol: CDXS) is a pioneering leader in protein engineering, pushing the boundaries of biotechnology through its innovative approaches. Established in 2002, Codexis specializes in the rapid development and production of highly optimized proteins using its proprietary CodeEvolver® technology platform. This platform leverages the power of artificial intelligence and advanced high-throughput screening systems to efficiently introduce function-driven mutations, creating proteins meticulously tailored to meet specific performance requirements.
Codexis offers a broad spectrum of enzyme optimization services and biocatalyst products. These include biocatalysts and enzymes, which play crucial roles in various industries, including pharmaceuticals, food, and biofuels. The company's enzyme solutions are designed to improve the efficiency, cost-effectiveness, and environmental sustainability of production processes.
A significant portion of Codexis’ revenue is derived from product sales, while licensing its technology platform to pharmaceutical companies also contributes to its financial health. These partnerships enable pharmaceutical giants to harness Codexis’ technology in-house, facilitating the engineering of custom enzymes for their specific needs.
Codexis has a global revenue footprint, with contributions from the United States, Ireland, Switzerland, China, and other international markets. The company's innovative efforts have led to several strategic partnerships and collaborations, further cementing its position in the biotechnology sector.
Recent achievements include a strategic collaboration geared towards enhancing RNA therapeutic development, aimed at providing GMP-grade Codexis enzymes. Another notable development is the collaboration with TnX transposase, focusing on enhancing genomic applications.
Codexis continues to advance in the field of biotherapeutics, retaining economic interest while minimizing development and commercialization costs. The company remains committed to optimizing yield, purity, and quality in its offerings, ensuring that customers receive superior siRNA materials for preclinical testing.
For more information, Codexis frequently participates in industry conferences, presenting breakthrough research and advancements. Stay updated with the latest developments and announcements by following Codexis on various platforms.
Codexis, Inc. (CDXS) reported a 23% increase in total revenue for Q1 2021, totaling $18.0 million, with product revenue doubling to $10.2 million. Notable growth was seen in the Performance Enzymes segment, which generated $14.2 million. The company's gross margin on product sales improved to 59%, up from 50% last year. Despite this growth, Codexis reported a net loss of $9.1 million or $0.14 per share. For 2021, the company maintains revenue guidance between $82 million and $85 million.
Codexis, Inc. (Nasdaq:CDXS) announced that it will report its Q1 2021 financial results on May 6, 2021, after market close. A conference call and webcast will occur at 4:30 p.m. ET to discuss the results and provide updates. The live webcast will be accessible via the Codexis Investor Relations website and archived for 90 days. Participants can also join by phone. Codexis leverages its CodeEvolver® technology for enzyme engineering in pharmaceuticals, fine chemicals, and diagnostics, emphasizing sustainable manufacturing.
Codexis, Inc. (CDXS) reported a strong fiscal year 2020, achieving total revenues of $69.1 million, marking a 1% increase from 2019. Product revenues rose to $30.2 million, boosted by higher sales of branded pharmaceutical products. The company achieved its highest product gross margin at 54.5%. R&D expenses increased to $44.2 million, while the net loss for the year was $24.0 million, or $0.40 per share. For 2021, Codexis forecasts total revenues between $82-85 million and product revenues between $36-39 million, with a gross margin of 54-58%.
Codexis, based in Redwood City, California, will present at three virtual investment conferences in late February and March 2021. Key events include the SVB Leerink Global Healthcare Conference on February 26 at 1:40 p.m. ET, the Cowen Health Care Conference on March 4 at 12:50 p.m. ET and 2:50 p.m. ET, and the H.C. Wainwright Life Sciences Conference on March 9-10. Live webcasts will be accessible on the company's Investor Relations webpage, with replays available for 30 days. Codexis specializes in enzyme engineering and sustainable manufacturing solutions.
Codexis, a leader in enzyme engineering, announced it will release its fourth quarter and full year 2020 financial results on February 25, 2021, post-market. Following the announcement, management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the live webcast through the Codexis Investor Relations website, and a replay will be available for 48 hours. Codexis uses its proprietary CodeEvolver technology for developing biocatalysts across pharmaceuticals and diagnostics.
Codexis (Nasdaq:CDXS) announced plans to expand operations with a new 36,000 square foot facility in San Carlos, CA, under a ten-year lease. This strategic move aims to enhance research and development capabilities, accommodating around 90 employees. The facility is expected to be ready by Q4 2021. CEO John Nicols highlighted the company's rapid growth in life sciences and sustainable manufacturing, anticipating continued acceleration through new partnerships and self-funded clinical programs.
Codexis (Nasdaq:CDXS) announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding the board to ten members. Dr. Martinborough brings over two decades of experience in drug discovery and development, having played a key role in the successful approval of Zeposia® for Multiple Sclerosis. Currently the Senior Vice President of Research at Escient Pharmaceuticals, her expertise is expected to contribute significantly to Codexis’ Biotherapeutics initiatives, enhancing its product development capabilities.
Codexis (CDXS) has extended its collaboration with Tate & Lyle, focusing on advancing the production of the DOLCIA PRIMA® Allulose and TASTEVA® M Stevia Sweetener. This partnership aims to improve production efficiencies through novel enzyme products developed by Codexis, potentially reducing costs linked to these sweeteners. Tate & Lyle’s new offerings target healthier consumer options, addressing diabetes and obesity issues. The collaboration, ongoing for seven years, underscores the importance of Codexis's enzyme technology in supporting Tate & Lyle's product development.
Codexis (Nasdaq:CDXS) announces that President and CEO John Nicols will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The recorded session will be accessible starting January 11 at 6:00 a.m. ET on the company's investor website, available for 30 days. Codexis specializes in protein engineering, utilizing its CodeEvolver® technology to enhance protein performance for pharmaceuticals, enzymes, and diagnostics, promoting sustainable manufacturing processes.
Codexis (Nasdaq: CDXS) announced a public offering of 4,285,715 shares at $17.50 each, aiming to raise approximately $70.2 million after expenses. The offering is expected to close around December 7, 2020, pending customary conditions. Proceeds will support R&D and infrastructure to enhance performance enzymes and biotherapeutics, as well as fund potential acquisitions or investments. Jefferies LLC, Cowen and Company, LLC, and Stifel are managing the offering, with an additional 642,857 shares available for underwriters within 30 days.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
What does Codexis, Inc. specialize in?
How does Codexis generate revenue?
What industries benefit from Codexis’ products and services?
What is the CodeEvolver® technology platform?
Where does Codexis derive its revenue from geographically?
What recent collaborations has Codexis entered into?
What is the significance of Codexis’ strategic collaborations?
What recent achievements has Codexis made in biotherapeutics?
How does Codexis ensure the quality of its products?
How can I stay updated with Codexis’ latest news and developments?
